Literature DB >> 19356614

Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.

Claudia Vellozzi1, Dale R Burwen, Azra Dobardzic, Robert Ball, Kimp Walton, Penina Haber.   

Abstract

In preparation for pandemic vaccine safety monitoring, we assessed adverse events reported to the Vaccine Adverse Event Reporting System following receipt of trivalent inactivated influenza vaccines among adults from 1990 through 2005. We calculated reporting rates for nonserious, serious, and neurological adverse events. We reviewed reports of recurrent events and deaths, as well as reports identified through advanced signal detection. The most frequently reported events were local reactions and systemic symptoms. Guillain-Barré syndrome was the most frequently reported serious event (0.70 reports per million vaccinations). Adverse event reporting rates have been reasonably constant over time. No new safety concerns emerged after our review of 15 years of post-licensure surveillance data. These findings provide useful information if pandemic vaccine is rapidly distributed and pre-licensure data are limited.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19356614     DOI: 10.1016/j.vaccine.2009.01.125

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  54 in total

1.  Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

Authors:  Sharon K Greene; Martin Kulldorff; Edwin M Lewis; Rong Li; Ruihua Yin; Eric S Weintraub; Bruce H Fireman; Tracy A Lieu; James D Nordin; Jason M Glanz; Roger Baxter; Steven J Jacobsen; Karen R Broder; Grace M Lee
Journal:  Am J Epidemiol       Date:  2009-12-04       Impact factor: 4.897

2.  "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events.

Authors:  David Evans; Simon Cauchemez; Frederick G Hayden
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

3.  Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Authors:  Luzhao Feng; Peng Yang; Tao Zhang; Juan Yang; Chuanxi Fu; Ying Qin; Yi Zhang; Chunna Ma; Zhaoqiu Liu; Quanyi Wang; Genming Zhao; Hongjie Yu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Deaths following vaccination: What does the evidence show?

Authors:  Elaine R Miller; Pedro L Moro; Maria Cano; Tom T Shimabukuro
Journal:  Vaccine       Date:  2015-05-23       Impact factor: 3.641

5.  Health-care worker vaccination for influenza: strategies and controversies.

Authors:  Catherine J Derber; Shivanjali Shankaran
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

Review 6.  Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly.

Authors:  Monique P Curran; Isabel Leroux-Roels
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

7.  From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.

Authors:  Bruce Y Lee; Kristina M Bacon; Julie M Donohue; Ann E Wiringa; Rachel R Bailey; Richard K Zimmerman
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

8.  Mandatory influenza vaccination for health care workers as the new standard of care: a matter of patient safety and nonmaleficent practice.

Authors:  Nicolas Cortes-Penfield
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

9.  First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.

Authors:  Geneviève Durrieu; Aurore Palmaro; Laure Pourcel; Céline Caillet; Angeline Faucher; Alexis Jacquet; Shéhérazade Ouaret; Marie Christine Perault-Pochat; Carmen Kreft-Jais; Anne Castot; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2012-10-01       Impact factor: 5.606

10.  Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation.

Authors:  Lisa S Jeffs; Jodie Nitschke; Jan Willem Cohen Tervaert; Chen Au Peh; Plinio R Hurtado
Journal:  Clin Rheumatol       Date:  2015-09-12       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.